Aims/hypothesis There are limited data comparing dipeptidyl
peptidase-4 (DPP-4) inhibitors directly. We compared the
safety and efficacy of vildagliptin and sitagliptin in patients
with type 2 diabetes and severe renal impairment (RI).
Methods This study was a parallel-arm, randomised,
multicentre, double-blind, 24 week study conducted in 87 centres
across Brazil and the USA. Patients with type 2 diabetes,
either drug naive or treated with any glucose-lowering agents,
who had inadequate glycaemic control (HbA1c 6.5–10.0%
[48–86 mmol/mol]) and an estimated GFR